The Curious Case of India and Big Pharma

We recommend to enable your javascript upon using this website to see full functionality.
Please click the link on how to enable it: https://www.enable-javascript.com/

Please wait while the page is loading...

The Curious Case of India and Big Pharma

14 September 2016

Amid criticism from the United States and elsewhere, India has debuted its first national IP policy. Simon Lee examines the interplay between the new IP policy and India’s lucrative pharmaceuticals industry.

To continue reading this article, please Login or Register to be a subscriber

Tags: Anand & Anand Subramaniam & Associates Corporate Law Group

Law firms

PIL filed in Delhi High Court addressing unauthorized use of artistic works by AI

12 November 2024

The Curious Case of India and Big Pharma

Law firms

India

Related Articles

Why your kids need to know their IP rights

Beyond well-knowness…

IP Experts 2019

PIL filed in Delhi High Court addressing unauthorized use of artistic works by AI